Stock XFOR X4 PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.2 USD +0.42% Intraday chart for X4 Pharmaceuticals, Inc. -2.83% +43.11%
Mar. 21 Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21 X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K
PU
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
AQ
Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
X4 Pharmaceuticals: Q4 Earnings Snapshot
AQ
North American Morning Briefing : Investors -2-
DJ
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
AQ
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
AQ
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
PR
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
North American Morning Briefing : Traders Await -2-
DJ
B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3
MT
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
AQ
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
AQ
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
CI
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XFOR Stock
  4. News X4 Pharmaceuticals, Inc.